Trial Profile
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2021
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications COVID 2019 infections; Multiple organ failure; SARS-CoV-2 acute respiratory disease; SARS-CoV-2 sepsis; Septic shock
- Focus Adverse reactions
- Acronyms NOXCOVID; NOXCOVID-1
- Sponsors Noxopharm
- 25 Aug 2021 According to a Noxopharm media release, based on initial positive results from this trial, company has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
- 25 Aug 2021 Results presented in a Noxopharm Media Release.
- 24 Aug 2021 Status changed from active, no longer recruiting to completed.